Filing identity and reporting period
Source mismatch: The request identifies Perspective Therapeutics, Inc. and 2017 Q3, but the supplied filing is IsoRay, Inc.’s Form 10-Q for the quarter ended March 31, 2018 (fiscal 2018 third quarter), filed May 4, 2018. The summary below reflects the supplied filing. Dollar figures are in thousands unless stated otherwise.
Business context
IsoRay manufactures and sells Cesium-131 brachytherapy seeds for cancer treatment. Its sales are concentrated in prostate brachytherapy; other applications include brain, lung, head and neck, and gynecological treatments. The company also had distributors in Italy and Russia, with approximately $35,000 of international revenue in the nine months ended March 31, 2018.
Financial results and liquidity
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Product sales, net | 2018: $1,573; 2017: $1,282 | 2018: $4,320; 2017: $3,391 |
| Gross profit / margin | 2018: $609 / 39%; 2017: $293 / 23% | 2018: $1,405 / 33%; 2017: $340 / 10% |
| Operating expenses | 2018: $1,948; 2017: $1,682 | 2018: $5,764; 2017: $4,783 |
| Operating loss | 2018: $(1,339); 2017: $(1,389) | 2018: $(4,359); 2017: $(4,443) |
| Net loss | 2018: $(1,332); 2017: $(1,360) | 2018: $(4,342); 2017: $(4,307) |
| Basic and diluted loss per share | 2018: $(0.02); 2017: $(0.02) | 2018: $(0.08); 2017: $(0.08) |
For the nine-month period, operating cash used was $4,264, compared with $4,499 in the prior year. Investing activities provided $658, largely reflecting certificate-of-deposit maturities net of purchases; financing activities provided $39. Cash and cash equivalents were $2,365 at March 31, 2018, down from $5,932 at June 30, 2017. Certificates of deposit totaled $2,150, bringing cash plus certificates of deposit to $4,515. Working capital was $5,202 and the current ratio was 5.63, versus $9,185 and 9.30 at June 30, 2017.
Total liabilities were $1,706, including $1,123 of current liabilities and a $583 asset retirement obligation. The balance sheet reports no debt. Total assets were $8,322, compared with $12,269 at June 30, 2017.
Material changes versus prior comparable periods
- Third-quarter sales rose 23%; nine-month sales rose 27%. Prostate sales increased 16% for the quarter and 24% year to date; other brachytherapy sales increased 70% and 50%, respectively.
- Gross margin improved substantially, while operating losses narrowed modestly. Nine-month net loss was slightly higher than the prior-year period.
- Nine-month R&D expense increased to $1,174 from $649, including higher proprietary and GammaTile collaboration costs. Sales and marketing expense increased to $1,980 from $1,550. General and administrative expense was broadly stable at $2,610 versus $2,632.
- Cash and working capital declined from fiscal year-end as operations continued to consume cash.
Outlook, commentary, risks, and unusual items
- Management projected fiscal 2018 revenue growth of at least 20% over fiscal 2017, noting the target was exceeded in the second and third quarters after a shortfall in the first. It estimated cash and certificates of deposit would cover projected operating needs through the remainder of fiscal 2018 and into the first half of fiscal 2019.
- Management said cash-flow break-even could be reached in three to five years if revenue growth targets are achieved; it cautioned there is no assurance growth will materialize.
- Near-term capital and listing risk: Despite its operating-liquidity forecast, the company said it believed it needed to raise capital within three months to maintain its NYSE American listing, assuming budgeted expenses and projected revenue. Potential financing could dilute shareholders; delisting could reduce trading liquidity and quotation availability.
- Management expected to invest approximately $360 in production automation over the next 14 months. It also had designed a future production and administration facility, but construction depended on obtaining financing.
- Five customers accounted for approximately 46% of nine-month revenue; one customer group represented approximately 24%. The filing warns that losing major customers could materially harm revenue, particularly given competition in prostate treatment.
- Cesium-131 supply relies on supplier arrangements, including an agreement extended through December 31, 2018. A separate consignment and services arrangement was expected to support supply over time, but the filing cautions that the full anticipated amount is not assured.
- The GammaTile collaboration with GammaTile, LLC continued, with FDA clearance activity ongoing and a Medicare new-technology payment application filed in October 2017. The filing reports $509 of collaboration costs for the nine-month period before reimbursement presentation.
- The company terminated its media advertising agreement in December 2017. It had paid $60 and issued 250,000 immediately vested warrants at $0.54 per share, expiring in October 2020; warrant compensation of approximately $72 was recognized for the nine-month period.
- A shareholder derivative lawsuit was dismissed in October 2017 and is resolved. The company reported no material legal proceedings as of the report date.
Important facts for investors to verify
- Confirm the filing identity and period: the supplied document is IsoRay’s March 31, 2018 Form 10-Q, not a Perspective Therapeutics 2017 Q3 filing.
- Review the company’s financing plans, NYSE American listing requirements, and whether capital was raised after the filing.
- Assess whether the 20% fiscal 2018 revenue-growth projection and three-to-five-year break-even outlook were achieved.
- Evaluate customer concentration, competitive pressure in prostate treatment, and the continuity and terms of Cesium-131 supply.
- Check subsequent progress on GammaTile regulatory and reimbursement applications, production automation, and facility financing.